in the next two months. this is no joke. big guys control the market now.
What's new guys? I don't see FDA hold . I only see trial in progress.
The second poster will feature an ongoing Phase 1/2 clinical trial (KEYNOTE-046) evaluating the combination of ADXS-PSA and Merck’s PD-1 checkpoint inhibitor KEYTRUDA® (pembrolizumab) in patients with previously treated, metastatic castration-resistant prostate cancer (mCRPC). The KEYNOTE-046 trial is the first-in-human study of ADXS-PSA and the second study initiated to evaluate the use of KEYTRUDA® in advanced prostate cancer.
just ask. IMO yes
Dr. Robert Ashworth has over 30 years of pharmaceutical industry experience spanning chemistry research and regulatory affairs. During the course of his career he has made significant contributions to the FDA approvals of twelve new drugs. His drug development and regulatory experience includes small molecules, therapeutic proteins and antibodies. He joined Advaxis from NPS Pharmaceuticals Inc., where he served as Vice President, Global Regulatory Affairs and spearheaded the global approval of drugs for rare diseases. Prior to that, he had similar roles at Otsuka Pharmaceutical Development and Commercialization, Inc. and Biovail Corporation. Earlier in his career, he held positions of increasing responsibility at Forest Laboratories Inc., BASF Pharma (Knoll) and Ciba-Geigy Corporation.
Dr. Ashworth holds a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology and a B.S. in Chemistry from St. John’s University.
I think it is about time ADXS to wake up. Dan trick or treat.
glad still have my 40k shares with AVXL, when i told chinaman to buythe price was $0.18. I guess never put eggs in on basket is absoluly correct now. Hope Dan can provide us so positive news next week. ADXS still my largest holding right now.
great news for Advaxis, guess who is next, ADXS IMO
have to correct this. this should be $35 stock already. IMO
you need to get the money first. You have a great product and you gave it away. we didn't get any money from Merck. What if Merck kick us out later. what you going to do DAN? just my thoughts.
i think there is a reason Adage don't want PPS go up for now, we don't know why and we don't know when it will go up. I guess we have to wait and see. IMO
If ADXS-HPV can extend your life, you give it a try! no product on market can kill cancer today. That's the reason we are here today!
That's what they are waiting for!
regarding the trial.
with Advaxis, super positive news for ADXS. can't wait the data coming out. Like what I said before,2-3billion dolllars buyout by Merck is possible.
Trenton, N.J. • The first combination of breakthrough drugs that boost the immune system to fight cancer has been approved, giving maker Bristol-Myers Squibb an early lead over competitors testing their own combos in a pharmaceutical gold rush of sorts.
The Food and Drug Administration has given accelerated approval to a regimen combining the New York-based drugmaker's two immuno-oncology drugs, Opdivo and Yervoy, to treat patients with advanced melanoma who have a particular genetic variation.
Together, the drugs slowed or temporarily stopped cancer progression in 60 percent of patients, versus 11 percent who only received Yervoy, in a study.
new insider buying